AL amyloidosis Market Is Expected to Grow during the Forecast Period (2019-2032), DelveInsight | Key Companies- Janssen Pharmaceutical, Prothena, and Several Others

The AL Amyloidosis market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted AL Amyloidosis symptoms market size from 2019 to 2032 segmented by seven major markets. The report also covers current AL Amyloidosis symptoms treatment practice/algorithm and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.

AL Amyloidosis: An Overview
Amyloid light-chain (AL) amyloidosis, also known as primary amyloidosis, is the most common form of systemic amyloidosis in the US. The disease is caused when a person's antibody-producing cells do not function properly and produce abnormal protein fibers made of components of antibodies called light chains.
Discover more information about the report @ https://www.delveinsight.com/sample-request/al-amyloidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Some of the key highlights of the AL Amyloidosis Market Report
• According to a study conducted by Shimazaki et al. (2019) titled, "Current diagnosis and treatment of AL amyloidosis in Japan: a nationwide epidemiological survey," the incidence of AL amyloidosis, in Japan, was estimated to be 2/million person-years.
• As per the National organization for rare disease information, while the incidence is thought to be equal in males and females, about 60% of patients referred to amyloid centers are male. AL amyloidosis has been reported in individuals as young as 20 years of age.
• According to the National Organization for Rare Disease, 60% of patients referred to amyloid centers are male.

AL Amyloidosis Epidemiology Segmentation in the 7MM
• Total Incident/Prevalent Cases
• Age-specific Incident/Prevalent Cases
• Gender-specific Incident/Prevalent Cases
• Diagnosed and Treatable Cases

AL Amyloidosis Treatment Market
AL amyloidosis treatment is tailored to the patient with their individual health in mind. The type of treatment is based upon disease progression and seriousness of the patient's organ, tissue, and nerve involvement. The treatment plans available are two-fold: Supportive treatment-treating the symptoms and organ damage-and, Source treatment-slowing down, or stopping, the overproduction of amyloid at the source of the disease. Supportive treatment is helpful for various symptoms, including cardiac and kidney problems, and can change the quality of life for many people. For example, gastrointestinal dysfunction may require treatment for symptoms that include poor nutritional health, diarrhea or constipation, and nausea or vomiting.

Request a Sample Copy of the Report- https://www.delveinsight.com/sample-request/al-amyloidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

AL Amyloidosis Market Insights
There is a strong need for regional AL Amyloidosis registration centers, which may offer consented and consistent therapy recommendations to gain more data and knowledge of this rare but threatening disease. Increased awareness of this unique histology has allowed for the development of drugs that are specific and has begun to shed light on the similarities and possible unique aspects of AL Amyloidosis.

Explore more about the report- https://www.delveinsight.com/report-store/al-amyloidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

AL Amyloidosis Emerging Drugs

Daratumumab: Janssen Pharmaceutical/Genmab
Daratumumab (Darzalex Faspro) is an IgG1k monoclonal antibody, first-CD38 directed targeted therapy, and binds to CD38. Daratumumab binds to a different CD38 epitope amino-acid sequence than causing cell apoptosis via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, or antibody-dependent cellular phagocytosis. These effects are dependent upon fragment crystallizable region immune effector mechanisms. Antibody-dependent cellular cytotoxicity utilizes natural killer cells.
In January 2021, Janssen Biotech announced that the Food and Drug Administration granted accelerated approval to daratumumab plus hyaluronidase in combination with bortezomib, cyclophosphamide, and dexamethasone for newly diagnosed light chain (AL) amyloidosis. Janssen Biotech announced updated positive results from the Phase III ANDROMEDA study, which is evaluating daratumumab and hyaluronidase-fihj for the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare blood cell disorder associated with the deterioration of vital organs, most notably the heart, kidneys, and liver. Longer-term results from a median follow-up of 20.3 months showed rates of hematologic complete response (hemCR) remained significantly higher in patients treated with Darzalex Faspro in combination with bortezomib, cyclophosphamide, and dexamethasone (D-VCd) compared to VCd alone.

Birtamimab: Prothena
Birtamimab, formerly known as NEOD001, is an investigational monoclonal antibody designed to specifically and selectively target and clear the amyloid that accumulates and causes organ dysfunction and failure in patients with AL amyloidosis.

Birtamimab has been tested in nearly 300 patients with AL amyloidosis at the intended clinical dose of 24 mg/kg and was shown to be generally safe and well-tolerated in the clinical studies conducted to date. Birtamimab was previously evaluated in Phase III VITAL Study, a global multi-center, randomized, double-blind, placebo-controlled clinical study of newly diagnosed, treatment naïve patients with AL amyloidosis and cardiac involvement. Results from the analysis of patients categorized as Mayo Stage IV at baseline in the VITAL study revealed a significant survival benefit favoring birtamimab in these patients, with 74% of birtamimab-treated patients alive at 9 months versus 49% of patients in the control group.

AL Amyloidosis Market Outlook
The report's AL Amyloidosis market outlook helps to better understand the historic, current, and forecasted AL Amyloidosis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This segment gives a thorough detail of AL Amyloidosis market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to view the market at first sight.

To Get More In-Depth Information about the report @ https://www.delveinsight.com/report-store/al-amyloidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

AL Amyloidosis Market Companies
• Janssen Pharmaceutical
• Prothena
• Alexion Pharmaceuticals
• Oncopeptides AB
• Bristol-Myers Squibb, and several others

Table of Content
1. Key Insights
2. Report Introduction
3. AL Amyloidosis Market Overview at a Glance
4. Executive Summary of AL Amyloidosis
5. Disease Background and Overview
6. Epidemiology and Patient Population
7. Patient Journey
8. Emerging Therapies
9. Other Promising Therapies
10. AL Amyloidosis: 7 Major Market Analysis
11. SWOT Analysis
12. Unmet Needs
13. KOL Views
14. Appendix
15. DelveInsight Capabilities
16. Disclaimer
17. About DelveInsight

To know how our report can help streamline your business-Speak to Analyst @ https://www.delveinsight.com/report-store/al-amyloidosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Contact Us
Yash
info@delveinsight.com

About Us
DelveInsight is a Business Consulting Services and Market research company, providing expert business solutions for the life science business development vertical and offering quintessential advisory services in the areas of R&D, Technical Due Diligence Firms, Strategy Formulation, Operations, Competitive Intelligence Pharma, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.